EN DE
Watch Bolt Biotherapeutics for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bolt Biotherapeutics (BOLT) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Bolt Biotherapeutics stock $6.06, price $6.43, that is 5.8% below the price, quality 49 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BB Bolt Biotherapeutics logo Thin data Nov 10, 2026

Bolt Biotherapeutics

BOLT · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Ranks above peers (5/7)
Fair value $6.06 · Fairly valued
Quality 49/100
Mixed Growth (revenue 5y +101.6 %/yr in USD)
Insiders sold $128,361 (6M)
Negative free cash flow
Narrow moat 0/100
Thin data
Estimate
Watch Bolt Biotherapeutics for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$372.00 $3.18 Fair Value $6.06 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $3.18 – $372.00 · fair‑value band $4.55 – $7.58 · the $6.43 price screens above the $6.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Bolt Biotherapeutics in your weekly email

Every Wednesday you see whether Bolt Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.

Show moreShow less

The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.

Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Stock analysis

Bolt Biotherapeutics (BOLT) currently trades at $6.43, while our estimate is $6.06, so the stock looks roughly fairly valued today (gap 6.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.55 (bear) to $7.58 (bull), the price of $6.43 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bolt Biotherapeutics reported revenue of $7.7M in FY2025 versus $1.3M in FY2021, a compound +57.2%/yr. Reported net income was −$33.4M in FY2025.

Key figures

Market cap $15.2M Micro · P/S ratio 3.28 · EPS (TTM) $−16.51 · Return on equity −112% · Return on assets (EBIT) −50.4% (5-year average) · Revenue (TTM) $4.7M · Free cash flow −$39.9M · Net debt $11.3M.

What moves the price

The share trades about 9% below its 52-week high and 102% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −6%, BOLT screens richer than that median.

Fair Value

Bear $4.55 Fair Value $6.06 Bull $7.58
Price $6.43 · Downside -5.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 77
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $128,361 and none bought.

  • SaleWilliam P. QuinnPresident, CEO and CFO, Director17,566 shares at $3.33$58,439Sep 18, 2026
  • SaleSarah NemecSenior VP, Finance and PAO7,842 shares at $3.33$26,089Sep 18, 2026
  • SaleGrant YonehiroChief Operating Officer13,176 shares at $3.33$43,834Sep 18, 2026
  • Plan buyWilliam P. QuinnPresident, CEO and CFO, Director2× since Dec 5, 2025: 762 shares, avg. $4.00$3,048Jun 5, 2026
  • Plan buySarah NemecSenior VP, Finance and PAO2× since Dec 5, 2025: 634 shares, avg. $4.02$2,551Jun 5, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+101.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21,290.9% (2020) → −450.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BOLT, get fair value alerts →

Compare Bolt Biotherapeutics with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 846 stocks

Beats the industry median on 5/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −5.8% · Top 25%
Profitability
Return on assets −58.8% · Bottom 25%
Operating margin (12 months) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.57× · Cheapest 25%
P/S (12 months) 3.23× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)26 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs BOLT
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs BOLT
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs BOLT
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs BOLT
argenx SE ARGX $962.27 $908.40 −6% vs BOLT
CSL Limited CSL A$200.73 A$181.40 −10% vs BOLT
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs BOLT
Moderna, Inc MRNA $269.00 $158.70 −41% vs BOLT
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs BOLT
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs BOLT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bolt Biotherapeutics: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bolt Biotherapeutics Fair Value". https://www.fairvalue-calculator.com/stock/BOLT

Frequently asked questions

Is Bolt Biotherapeutics (BOLT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $6.06 versus a price of $6.43, about 6% lower (fairly valued).
What is the fair value of BOLT?
Our estimate for Bolt Biotherapeutics is $6.06 (as of Nov 10, 2026), built from audited fundamentals. The current price: $6.43.
What is the quality score of BOLT?
Bolt Biotherapeutics has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bolt Biotherapeutics (BOLT)?
Our calculated price target is the estimate of $6.06 (as of Nov 10, 2026). Cautious scenario $4.55, optimistic scenario $7.58. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Bolt Biotherapeutics stock forecast for 2026?
Our estimate puts fair value at $6.06, about 6% lower versus a price of $6.43 (fairly valued). Cautious scenario $4.55, optimistic scenario $7.58. The calculation is refreshed regularly with new filings.
What is the revenue of Bolt Biotherapeutics (BOLT)?
Bolt Biotherapeutics reported trailing-twelve-month revenue of about $4.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Bolt Biotherapeutics (BOLT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bolt Biotherapeutics it is $6.06 per share (as of Nov 10, 2026), against a price of $6.43.
Is Bolt Biotherapeutics stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BOLT trades above its calculated fair value: price $6.43, fair value $6.06, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BOLT?
No. The price is what the market pays today ($6.43); the fair value is what the company's own numbers justify ($6.06). For Bolt Biotherapeutics the two are $0.3700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bolt Biotherapeutics worth?
The market values Bolt Biotherapeutics at about $15.2M (market capitalisation, as of Nov 10, 2026). Per share that is $6.43; our models calculate a fair value of $6.06 per share.
What do the bullish and bearish scenarios say about BOLT?
Our models span a range for Bolt Biotherapeutics: cautious scenario $4.55, base $6.06, optimistic $7.58 per share (as of Nov 10, 2026, price $6.43). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bolt Biotherapeutics (BOLT)?
Balance-sheet figures for Bolt Biotherapeutics (as of Nov 10, 2026): return on equity −111.7%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is BOLT from its 52-week high?
Bolt Biotherapeutics trades at $6.43, about 9% below its 52-week high of $7.09 and 102% above the low of $3.18 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $6.06 is for.
Which stocks are comparable to Bolt Biotherapeutics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bolt Biotherapeutics stock attractive at the current price?
The data as of Nov 10, 2026: price $6.43, calculated fair value $6.06 (−6%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.2% above its aggregate fair value. Bolt Biotherapeutics itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bolt Biotherapeutics (BOLT)?
The closing price on Nov 9, 2026 was $6.43. Our estimate is $6.06, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bolt Biotherapeutics right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Bolt Biotherapeutics

How large is the market capitalisation of Bolt Biotherapeutics (BOLT)?
The market capitalisation of Bolt Biotherapeutics is $15.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bolt Biotherapeutics (BOLT)?
The price-to-sales ratio of Bolt Biotherapeutics is 3.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bolt Biotherapeutics (BOLT)?
Earnings per share at Bolt Biotherapeutics are $−16.51. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bolt Biotherapeutics (BOLT)?
The return on equity (ROE) of Bolt Biotherapeutics is −112% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bolt Biotherapeutics (BOLT)?
On an EBIT basis the return on assets of Bolt Biotherapeutics is −50.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Bolt Biotherapeutics (BOLT) generate?
The free cash flow of Bolt Biotherapeutics is −$39.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bolt Biotherapeutics (BOLT) carry?
The net debt of Bolt Biotherapeutics is $11.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bolt Biotherapeutics in the live analysis

One click puts Bolt Biotherapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.